Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization
- PMID: 7514675
- PMCID: PMC236848
- DOI: 10.1128/JVI.68.6.3459-3466.1994
Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization
Abstract
Neutralization of a chimeric human immunodeficiency virus (HIV) type 1, containing the V3 loop of the MN isolate substituted within the HXB2 envelope, was enhanced up to 20-fold compared with the HXB2 or MN parental isolates by human HIV-positive sera. MN V3 loop-specific monoclonal antibodies were better able to recognize the chimeric virus compared with MN, staining a greater percentage of infected cells and exhibiting slight increases in relative affinity with a concomitant increase in neutralization titer. Competition analysis revealed that enhanced neutralization by human HIV-positive sera of the chimera was attributable in some cases to better reactivity with the linear V3 loop epitope but in others to conformational loop epitopes or previously cryptic or poorly recognized epitopes outside the loop region. Mice primed with a vaccinia virus-chimeric envelope recombinant and boosted with gp160 developed a spectrum of antibodies different from that of mice similarly immunized with HXB2 or MN recombinants or that of naturally infected humans. The chimeric envelope elicited antibodies with enhanced binding to the native MN V3 loop; however, the sites seen by the BALB/c mice were not neutralizing epitopes. Nevertheless, similar to the observations made with use of human sera, the chimeric virus was more readily neutralized by all of the immune mouse sera, an effect apparently mediated by non-V3 loop epitopes. These studies illustrate that not only the V3 loop sequence and conformation but also its context within the viral envelope influence neutralization.
Similar articles
-
Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.J Virol. 1998 Dec;72(12):9855-64. doi: 10.1128/JVI.72.12.9855-9864.1998. J Virol. 1998. PMID: 9811721 Free PMC article.
-
Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.AIDS Res Hum Retroviruses. 1994 May;10(5):577-83. doi: 10.1089/aid.1994.10.577. AIDS Res Hum Retroviruses. 1994. PMID: 7522494
-
Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.J Virol. 1995 Jun;69(6):3299-307. doi: 10.1128/JVI.69.6.3299-3307.1995. J Virol. 1995. PMID: 7745677 Free PMC article.
-
Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.J Virol. 1992 Jul;66(7):4003-12. doi: 10.1128/JVI.66.7.4003-4012.1992. J Virol. 1992. PMID: 1602531 Free PMC article.
-
Biological consequences of human immunodeficiency virus type 1 envelope polymorphism: does variation matter? 1995 Fleming Lecture.J Gen Virol. 1996 Dec;77 ( Pt 12):2905-19. doi: 10.1099/0022-1317-77-12-2905. J Gen Virol. 1996. PMID: 9000081 Review. No abstract available.
Cited by
-
Spontaneous reversion of human immunodeficiency virus type 1 neutralization-resistant variant HXB2thr582: in vitro selection against cytopathicity highlights gp120-gp41 interactive regions.J Virol. 1995 Mar;69(3):1860-7. doi: 10.1128/JVI.69.3.1860-1867.1995. J Virol. 1995. PMID: 7853527 Free PMC article.
-
An infectious chimeric human immunodeficiency virus type 2 (HIV-2) expressing the HIV-1 principal neutralizing determinant.J Virol. 1995 Oct;69(10):6424-9. doi: 10.1128/JVI.69.10.6424-6429.1995. J Virol. 1995. PMID: 7666543 Free PMC article.
-
Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.J Virol. 1995 Oct;69(10):6342-51. doi: 10.1128/JVI.69.10.6342-6351.1995. J Virol. 1995. PMID: 7666535 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources